Juvenile chronic myelomonocytic leukemias: molecular and novel therapeutic basis.
Myelomonocytic leukemias of children represent a distinct disorder from chronic myelogenous leukemia and adult myelomonocytic leukemias. The prognosis is poor and no therapy has proved to be yet effective. This review summarizes the molecular and cellular characteristics of this disease which may allow to design more targetted therapeutic agents.
Chomienne
C
C
Laboratoire de Biologie Cellulaire Hématopoïétique EP CNRS 107, Hôpital Saint-Louis, Paris, France.
Cambier
N
N
Baruchel
A
A
D002648:Child; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000378:metabolism; D015477:Leukemia, Myelomonocytic, Chronic / Q000235:genetics / Q000378:metabolism* / Q000473:pathology / Q000628:therapy*